



# Proposed Proprietary Laboratory Analyses Panel Meeting Agenda - August 2026 Meeting

The proposed agenda for the August 2026 CPT® Proprietary Laboratory Analyses Panel meeting identifies the test names and requested descriptions for each test. The laboratory test name and test description detailed in this document are extracted from Applications submitted for discussion at this meeting. **The information contained in this Proposed Agenda is provided for informational purposes only until the Technical Advisory Group (TAG) has completed its review. The TAG will deliberate on these requests and provide its recommendations to the CPT Editorial Panel after its meeting on July 21, 2026.**

## NOTICE –INTERESTED PARTY PROCESS

Upon review of this agenda, if the reviewer believes that they may want to provide written comments on an application, the reviewer must seek Interested Party status by submitting a request form. The form requires identification of the potential Interested Party, a brief summary of the basis for the request (e.g., associated vendor/ industry representative), and signature of the confidentiality agreement and disclosure of interest forms. For more information, [please visit our website](#).

**The deadline to submit comments for the upcoming August 2026 Panel meeting is July 20, 2026. Only requests submitted via the CPT Smart App’s [Interested Party Portal](#) will be considered.** Any recognized Interested Party who provides written comments must do so no later than the deadlines below and in the Interested Party Portal. Should you miss the comment deadline, verbal comments can be provided in person at the Panel meeting.

App ID	Laboratory Test name	Code Request	Proposed Test Description
a393033	Lyme ImmunoBlot IgM	D0041U	<del>Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM</del>
a538633	Lyme ImmunoBlot IgG	D0042U	<del>Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG</del>
a763436	Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgM Test	D0043U	<del>Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM</del>
a478955	Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgG Test	D0044U	<del>Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG</del>
a962600	DecisionDx® DiffDx™-Melanoma	D0314U	<del>Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded</del>

			(FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)
a905668	IMMray® PanCan-d	D0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline
a822189	PROSTOX™ ultra	D0534U	Oncology (prostate), microRNA, single-nucleotide polymorphisms (SNPs) analysis by RT-PCR of 32 variants, using buccal swab, algorithm reported as a risk score
a500194	PGT-M	D0552U	Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder
a622583	IVD CAPSULE PSP – Rapid Sepsis Test	D0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
a778124	PredicineBEACON Baseline	D0641U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), using formalin-fixed paraffin-embedded (FFPE) tissue and blood samples, initial (baseline) assessment
a455909	PredicineBEACON MRD (Longitudinal)	D0642	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), whole blood, comparison to previously performed analyses, reported as trend in circulating tumor DNA (ctDNA) level
a155094	Oncuria® Detect <i>Lab Name Change Only</i>	▲0365U	Oncology (bladder), 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm, including patient's age, race, and gender, reported as a probability of harboring urothelial cancer
a374113	Oncuria® Monitor <i>Lab Name Change Only</i>	▲0366U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer
a552768	Oncuria® Predict <i>Lab Name Change Only</i>	▲0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection
a132602	Solid Tumor Expanded Panel or Solid TumorSEQ™	▲0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence

	<i>Test Name Change Only</i>		variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden
a110140	xT CDx	▲0473U	Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen <del>when available (blood or saliva)</del> , 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and <del>tumor mutational</del> <del>tumor mutation</del> burden
a826633	Oncodetect® Molecular Residual Disease Test – Baseline	▲0688U	Oncology, analysis of minimal residual disease (MRD), next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis in whole blood and tumor for baseline assessment to evaluate current MRD status and for comparisons to subsequent MRD assessments
a649619	Oncodetect® Molecular Residual Disease Test – Monitoring	▲0689U	Oncology, analysis of minimal residual disease (MRD) using patient-specific assays, reported as amount of circulating tumor DNA (ctDNA) detected and trend over time
a372610	Alcohol T-Score (Saliva)™	▲685U	Alcohol use disorder, DNA analysis of 5 methylation markers (4 content: cg02583484, cg04987734, cg09935388, cg04583842, and 1 normalizing: cg08141395), methylation-sensitive digital PCR, <del>blood or</del> saliva, algorithm reported as a summed T-score
a003266	PC Rapid Whole Genome Sequencing (rWGS)	NEW	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis
a032244	MAL18S Plasmodium 18S rRNA quantitative RT-PCR assay	NEW	Infectious disease ( <i>Plasmodium</i> species), ultrasensitive real-time quantitative reverse transcription PCR for detection of 18S ribosomal RNA from human-infecting species of <i>Plasmodium</i> ( <i>P. falciparum</i> , <i>P. vivax</i> , <i>P. ovale curtisi</i> , <i>P. ovale wallikeri</i> , <i>P. malariae</i> , <i>P. knowlesi</i> ), blood, quantitative reporting for the presence of pan-genus infections (pan- <i>Plasmodium</i> ) and the presence of <i>P. falciparum</i>
a036900	TruProstate Assay	NEW	Oncology (prostate), quantitative analysis of PCA3, ERG, and SPDEF ribonucleic acid (RNA) biomarkers from first-catch urine, utilizing target capture, transcription-mediated amplification, and digital droplet isothermal amplification quantitative detection (ddSAT), with algorithmic analysis and reported as a proprietary prostate cancer risk score

a052942	Accu Urinary Tract Infection Panel PCR with reflex to antibiotic sensitivity by microbiology	NEW	Infectious disease (urinary tract infection) identification of 24 bacterial and fungal organisms, urine, real time PCR, with reflex to antimicrobial susceptibility testing, qualitative reporting for each organism
a108246	elive™	NEW	Oncology, solid tumor, ex vivo treatment-response profiling, fresh tumor tissue, with hydrogel encapsulation to maintain cell microenvironment, serial cytokine measurements, with algorithmic assessment and report of therapeutic response, per therapy tested (e.g., aPD-1, aCTLA4, or aPD-1 + aCTLA4)
a116003	Nova Dx™ Lung	NEW	Oncology (lung cancer), DNA methylation analysis of at least 12,000 sites, whole blood, algorithm, reported as a risk score for lung cancer
a131544	Promarker®Eso	NEW	Gastroenterology (esophageal adenocarcinoma), liquid chromatography-tandem mass spectrometry analysis of 4 serum glycoprotein biomarkers (alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9 and plasma kallikrein) combined with clinical factors (age, sex and body mass index), algorithm reported as a probability for esophageal adenocarcinoma
a187180	UTI Plus	NEW	Infectious disease (urinary tract infection) identification of 21 pathologic organisms, urine, real time PCR, with 22 ABX (antibiotic) resistance gene markers, qualitative reporting for each organism
a239415	GenomeDx™ ultraRapid, comparator	NEW	Rare diseases (constitutional/heritable disorders), ultrarapid whole genome sequence analysis of comparator nuclear and mitochondrial DNA by next-generation sequencing (NGS), using blood or buccal sample, relevant variants reported with proband results  (Use XXXX in conjunction with 0659U)
a249465	Delve Detect Cerebrospinal Fluid	NEW	Agnostic infectious disease pathogen detection and identification by DNA and RNA metagenomic next-generation sequencing (bacteria, fungi, RNA viruses, DNA viruses, parasites) including specimen stabilization, specimen shipping, cellular lysis, nucleic acid extraction, separate RNA and DNA library preparation with reverse transcriptase PCR and PCR, next generation sequencing, bioinformatic alignment of sequencing data to curated pathogen database, cerebrospinal fluid, identification of pathogenic microbial organisms with clinical interpretation and report

a275791_1	UTI by PCR	NEW	Infectious disease (urinary tract infection), identification of 27 pathologic organisms, urine, real-time PCR, reported as detected or not detected for each organism
a275791_2	ABR by PCR Reflex	NEW	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, ordered as reflex testing for positive UTI by PCR reported as an antimicrobial stewardship risk score
a284823	CancerVision	NEW	Oncology (solid tumor), target-enhanced whole genome sequencing analysis including deep sequencing of 526 genes, interrogation of somatic variants (single nucleotide variants, insertions/deletions, copy number variants), genomic instability markers (tumor mutational burden, microsatellite instability, homologous recombination deficiency), and select germline variants, utilizing formalin-fixed paraffin-embedded (FFPE) or fresh frozen tumor tissue and matched normal blood or buccal swab, clinically significant mutations and therapy associations reported
a323988	Bach Diagnostics Wound PCR Test	NEW	Infectious disease,(bacteria and fungi), antibiotic sensitivity, real-time PCR for detection of DNA from 27 species of bacteria and fungi, 17 resistance genes, wound swab, semi-quantitative reporting of bacterial load and qualitative reporting of detected or not detected resistance genes that reports antibiotic options
a333481	SAGE Oncotest Prevail	NEW	Oncology, solid tumor or cancer of unknown primary, 5-ethynyl-2'-deoxyuridine (EdU) incorporation into newly synthesized DNA, click chemistry fluorescence detection and confocal imaging analysis of fresh viable tumor tissue, core needle biopsy, or malignant body fluid following ex vivo exposure to a panel of antiproliferative and targeted therapeutic agents, with dose-response area-under-the-curve algorithm reported as drug-specific sensitivity, intermediate response, or resistance classification
a412592	RaDaR ST	NEW	RaDaR ST PLA Code Descriptor- Oncology (pan-cancer), tumor-informed next-generation sequencing (NGS) analysis of cell-free DNA (cfDNA) for detection of molecular residual disease (MRD) from plasma, with assays personalized to each patient utilizing up to 48 patient-specific somatic variants identified by prior whole exome sequencing (WES) of the patient's tumor tissue, reported as absence or presence of MRD, with disease-burden correlation

a428075	JAYseq™ Rapid WGS for Multiple Myeloma	NEW	Oncology (multiple myeloma), rapid whole genome sequencing of bone marrow aspirate for detection and interpretation of single nucleotide variants, insertions/deletions, structural variants, and copy number alterations clinically significant in multiple myeloma, algorithm reported as high-risk status, prognostic category, and therapeutic target status
a510909_1	FLT3 <sup>Ⓜ</sup>	NEW	<i>FLT3</i> ( <i>fms-related tyrosine kinase 3</i> ) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative
a510909_2	NPM1 <sup>Ⓜ</sup>	NEW	<i>NPM1</i> ( <i>nucleophosmin</i> ) (eg, acute myeloid leukemia) gene analysis, quantitative
a594366	OvasomDx	NEW	Oncology (ovarian), exosome-based biochemical analysis of three proteins (CA125, HE4, C5a), serum, algorithm reported as score indicating presence of epithelial ovarian cancer
a679223	SAGE Oncotest Reveal	NEW	Oncology, solid tumor, intracellular adenosine triphosphate (ATP), bioluminescent cell viability assay of fresh tumor tissue, core needle biopsy, or malignant body fluid following ex vivo exposure to cytotoxic and targeted therapeutic agents, algorithm reported as drug-specific sensitivity, intermediate response, or resistance classification
a745441	UTI Plus STI	NEW	Infectious disease UTI (urinary tract infection) plus STI (sexually transmitted infection) identification of 25 pathologic organisms, urine, real time PCR, with 22 ABX (antibiotic) resistance gene markers, qualitative reporting for each organism
a784125	Guardant360 Liquid CDx	NEW	Oncology (solid tumor), cell-free DNA from plasma, targeted genomic and epigenomic sequence analysis, 741 or more genes, interrogation for sequence variants, insertions/deletions, copy number amplifications/losses, fusions/rearrangements, microsatellite instability and tumor mutational burden
a858990	ProstateDX (PSB)	NEW	Oncology (prostate), microRNA profiling by qPCR of up to 12 microRNA biomarkers (8 content, 2 housekeeping, 2 spike-in) released post-sonication (from a ultrasound exposure) relative to pre-sonication baselines, utilizing plasma and buffy-coat samples

			from a blood sample, additionally measuring prostate specific antigen (PSA) and using a prognostic algorithm reported as a score
a911219	SpermQT (Sperm Quality Test)	NEW	Male infertility, sperm DNA methylation analysis of 319 CpG sites by bisulfite conversion and genome-wide microarray, including computational assessment of methylation variability, sperm from semen, reported as categorical sperm quality classification (Excellent, Normal, Abnormal)